Log In Get Started

News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • No market-moving news released in the past hour.
  • No economic data or central-bank statements were published in the last hour.
  • No geopolitical or global-event developments reported in the past hour.
  • No new political headlines or legislative actions occurred in the past hour.
  • No significant corporate filings, earnings, or M&A announcements were reported in the last hour.
  • News flow quiet across commodities and FX in the past hour.

Latest Articles

22nd Century CEO & Chairman Larry Firestone: Improved Gross Margin, ~5,000 Retail Outlets and >$50B Market Opportunity Highlight Mid-Year Stockholder Letter
Sep 1, 2026
Priya Menon
Press Releases

22nd Century CEO & Chairman Larry Firestone: Improved Gross Margin, ~5,000 Retail Outlets and >$50B Market Opportunity Highlight Mid-Year Stockholder Letter

22nd Century Group, a Nasdaq-listed leader in low-nicotine tobacco products, reports accelerating growth with expanded retail presence from 2,000 to an expected 5,000 outlets by year-end 2026, improved gross margins driven by branded products, and consistent monthly sales growth. The company remains focused on commercial execution and innovation, l…

XXII
Wetour Robotics Demonstrates sEMG-Vision System Targeting Force and Occlusion Blind Spots in Physical AI Training
Sep 1, 2026
Maya Rios
Press Releases

Wetour Robotics Demonstrates sEMG-Vision System Targeting Force and Occlusion Blind Spots in Physical AI Training

Wetour Robotics Limited has demonstrated its Orchestra system, integrating surface electromyography (sEMG) wristband data with first-person vision to overcome limitations of vision-only robot training. The fusion of muscle activation data with visual input enables more accurate capture of hand movement and force, even during occlusions, improving d…

WETO
Biometric Identity Security Provider BIO-key Participates at H.C. Wainwright Global Investment Conference Sept. 15th and 17th
Sep 1, 2026
Maya Rios
Press Releases

Biometric Identity Security Provider BIO-key Participates at H.C. Wainwright Global Investment Conference Sept. 15th and 17th

BIO-key International, a leader in biometric identity and access management solutions, announced that CEO Michael DePasquale will participate in virtual meetings and present at the H.C. Wainwright Global Investment Conference in September 2026. The company's presentation will be available on demand to registered attendees, highlighting its biometri…

BKYI
Emergent BioSolutions Awarded Contract Modification Valued at Approximately $24 Million for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted)
Sep 1, 2026
Hana Yamamoto
Press Releases

Emergent BioSolutions Awarded Contract Modification Valued at Approximately $24 Million for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted)

Emergent BioSolutions has been awarded a $24 million contract modification by BARDA, part of the U.S. Department of Health and Human Services, to supply its CYFENDUS® anthrax vaccine. This contract supports the U.S. government's ongoing anthrax preparedness efforts amid biological threats. CYFENDUS®, FDA-approved in 2023 for post-exposure prophylax…

EBS
3 E Network Secures $1.2 Million Enterprise DDR4 Memory Sales Order
Sep 1, 2026
Nina Shah
Press Releases

3 E Network Secures $1.2 Million Enterprise DDR4 Memory Sales Order

3 E Network Technology Group Limited announced that its wholly owned subsidiary secured a $1.2 million sales order for enterprise-grade DDR4 memory chips. This order demonstrates the company's capabilities in hardware supply amid growing IT infrastructure upgrades and provides additional revenue to support its AI infrastructure R&D efforts. The ord…

MASK
Kayne Anderson Energy Infrastructure Fund Announces Distribution of $0.09 Per Share for September 2026
Sep 1, 2026
Avery Klein
Press Releases

Kayne Anderson Energy Infrastructure Fund Announces Distribution of $0.09 Per Share for September 2026

Kayne Anderson Energy Infrastructure Fund, Inc. declared a monthly distribution of $0.09 per common share payable on September 30, 2026. The fund focuses on energy infrastructure securities and aims to provide high after-tax returns with an emphasis on cash distributions. Distribution amounts may vary and are subject to Board approval and financial…

KYN
Kala Bio and Virotek Announce Letter of Intent to Establish an Exclusive U.S. Distribution Partnership for Ophthalmology Genetic Testing Program
Sep 1, 2026
Avery Klein
Press Releases

Kala Bio and Virotek Announce Letter of Intent to Establish an Exclusive U.S. Distribution Partnership for Ophthalmology Genetic Testing Program

Kala Bio and Virotek announced a letter of intent to establish an exclusive U.S. distribution partnership where Kala will market and distribute Virotek's genetic testing program for ophthalmology. This collaboration aligns with Kala's strategic focus on eye care and provides a near-term commercial revenue opportunity while extending Kala's reach in…

KALA
NorthStrive Biosciences Expands AI-Driven Drug Discovery Program with Yuva Biosciences, Advancing Four Novel AI-Discovered Compounds Toward Lead Nomination for Potential Cardiac Disease and Obesity Therapeutic Applications
Sep 1, 2026
Maya Rios
Press Releases

NorthStrive Biosciences Expands AI-Driven Drug Discovery Program with Yuva Biosciences, Advancing Four Novel AI-Discovered Compounds Toward Lead Nomination for Potential Cardiac Disease and Obesity Therapeutic Applications

NorthStrive Biosciences, a subsidiary of PMGC Holdings (NASDAQ: ELAB), announced an expanded three-phase program with Yuva Biosciences to advance four AI-discovered compounds toward lead nomination for developing potential therapies in cardiac diseases and obesity. The program builds upon positive Phase III results and aims to de-risk and narrow ca…

ELAB
Clearmind Reaches Key Milestone: CMND-100 Phase IIa now Underway for Alcohol Use Disorder Trial, One-Third of Part C Enrolled
Sep 1, 2026
Hana Yamamoto
Press Releases

Clearmind Reaches Key Milestone: CMND-100 Phase IIa now Underway for Alcohol Use Disorder Trial, One-Third of Part C Enrolled

Clearmind Medicine Inc. has initiated Phase IIa of its Phase I/IIa clinical trial evaluating CMND-100, a non-hallucinogenic psychedelic-derived therapeutic candidate, for the treatment of Alcohol Use Disorder (AUD). Six patients have been enrolled so far across medical centers in Israel, marking progression into the multiple-dose treatment phase fo…

CMND
Gran Tierra: Asset Sales Could Be the Catalytic Reset the Stock Needs
Sep 1, 2026
Ajmal Hussain
Trade Ideas

Gran Tierra: Asset Sales Could Be the Catalytic Reset the Stock Needs

Gran Tierra Energy's plan to sell its Colombia and Ecuador businesses, combined with improving Q2 results and cheap valuation metrics (EV/EBITDA ~2.8, P/S 0.56), creates a clear asymmetric trade. If proceeds are used to pay down debt and simplify the asset base, the market could re-rate the stock. This trade targets reopening the re-rating over the…

GTE
Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
Sep 1, 2026
Caleb Monroe
Press Releases

Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)

Stoke Therapeutics and Biogen presented 4-year clinical data showing sustained improvements in cognition, behavior, and durable seizure reductions with a generally well-tolerated safety profile for zorevunersen, an investigational antisense oligonucleotide targeting the underlying cause of Dravet syndrome. The ongoing global Phase 3 EMPEROR study a…

STOK, BIIB
COMSTOCK ANNOUNCES $1.65 BILLION STRATEGIC PARTNERSHIP WITH SOCAR AND $450 MILLION DRILLING JOINT VENTURE WITH JERRY JONES
Sep 1, 2026
Leila Farooq
Press Releases

COMSTOCK ANNOUNCES $1.65 BILLION STRATEGIC PARTNERSHIP WITH SOCAR AND $450 MILLION DRILLING JOINT VENTURE WITH JERRY JONES

Comstock Resources announced a strategic partnership with SOCAR involving the sale of non-operated interests in its Legacy and Western Haynesville assets and Pinnacle Gas Services for $1.65 billion in cash. Additionally, Comstock entered a $450 million drilling joint venture with majority stockholder Jerry Jones to fund drilling of Haynesville well…

CRK
Telesat Government Solutions and Cailabs Collaborate on Secure Optical Connectivity for Government Missions
Sep 1, 2026
Derek Hwang
Press Releases

Telesat Government Solutions and Cailabs Collaborate on Secure Optical Connectivity for Government Missions

Telesat Government Solutions, a US-based subsidiary of Telesat Corporation (TSAT), has signed a strategic collaboration with Cailabs US, Inc. to integrate secure, resilient, high-capacity optical space-to-ground connectivity for U.S. Government and allied missions. The partnership aims to combine Telesat's Lightspeed LEO satellite network with Cail…

TSAT
Streamex Corp. Appoints Laura Kiernan as Head of Investor Relations
Sep 1, 2026
Nina Shah
Press Releases

Streamex Corp. Appoints Laura Kiernan as Head of Investor Relations

Streamex Corp., a Nasdaq-listed technology company specializing in tokenization of commodity assets, appointed Laura Kiernan as Head of Investor Relations. Kiernan brings over 30 years of capital markets experience to lead investor relations strategy, aiming to bridge the value of Streamex's platform with market perception. The move supports Stream…

STEX
Ardelyx to Participate in Upcoming Investor Conferences
Sep 1, 2026
Derek Hwang
Press Releases

Ardelyx to Participate in Upcoming Investor Conferences

Ardelyx Inc., a US commercial-stage biopharmaceutical company, has announced its participation in several major investor conferences in New York during September 2026, including Citi, Cantor, and Morgan Stanley healthcare events. The company will host fireside chats and investor meetings, providing updates on its commercial products IBSRELA and XPH…

ARDX
BridgeBio to Participate in September Investor Conferences
Sep 1, 2026
Ajmal Hussain
Press Releases

BridgeBio to Participate in September Investor Conferences

BridgeBio Pharma, a biopharmaceutical company focused on genetic condition medicines, announced that its management will participate in several upcoming healthcare investor conferences in September 2026. These include Wells Fargo, Cantor Global, Morgan Stanley, and Bernstein Insights conferences. The company aims to communicate its developments and…

BBIO
KANZHUN LIMITED Announces Change of Directors’ Executive Positions
Sep 1, 2026
Sofia Navarro
Press Releases

KANZHUN LIMITED Announces Change of Directors’ Executive Positions

KANZHUN LIMITED, a leading Chinese online recruitment platform, announced the rotation of its president position effective September 1, 2026. Mr. Xu Chen steps down as president but remains as executive director and Chief Marketing Officer, while Mr. Tao Zhang takes over as rotating president alongside his roles as executive director and Chief Tech…

BZ
Alumis Announces Topline Results from Envudeucitinib Phase 2b Trial in Systemic Lupus Erythematosus (SLE)
Sep 1, 2026
Maya Rios
Press Releases

Alumis Announces Topline Results from Envudeucitinib Phase 2b Trial in Systemic Lupus Erythematosus (SLE)

Alumis announced that its Phase 2b LUMUS trial of envudeucitinib in moderate-to-severe systemic lupus erythematosus (SLE) did not meet primary and secondary endpoints in the overall population. However, robust responses in the prespecified interferon gene signature-high (IFNGS-high) subgroup, representing most moderate-to-severe SLE cases, support …

ALMS
Vera Therapeutics to Participate at Upcoming Investor Conferences
Sep 1, 2026
Avery Klein
Press Releases

Vera Therapeutics to Participate at Upcoming Investor Conferences

Vera Therapeutics, a US-based commercial-stage biotech company specializing in autoimmune kidney diseases, will present at the Cantor Global Healthcare Conference and the Morgan Stanley Global Healthcare Conference in September 2026. The company's management aims to engage investors through fireside chats and one-on-one meetings, highlighting their…

VERA